Form 4 Filing for Black Diamond Therapeutics, Inc.

On June 26, 2026, Kulkarni Samarth, a director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options with a strike price of $1.71 per share. These options are exercisable upon the earlier of June 26, 2027, or the company's next annual meeting of stockholders, provided continued service. The options expire on June 25, 2036. This transaction is reported on a Form 4 filing, with the signature date of June 29, 2026. The underlying security is Common Stock.